ID   K/VP.5
AC   CVCL_C6JT
DR   Wikidata; Q116049609
RX   PubMed=8058057;
RX   PubMed=8142256;
CC   Population: Caucasian.
CC   Doubling time: 22 hours (PubMed=8142256).
CC   Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 02-05-24; Version: 4
//
RX   PubMed=8058057;
RA   Ritke M.K., Allan W.P., Fattman C.L., Gunduz N.N., Yalowich J.C.;
RT   "Reduced phosphorylation of topoisomerase II in etoposide-resistant
RT   human leukemia K562 cells.";
RL   Mol. Pharmacol. 46:58-66(1994).
//
RX   PubMed=8142256; DOI=10.1038/bjc.1994.131;
RA   Ritke M.K., Roberts D., Allan W.P., Raymond J., Bergoltz V.V.,
RA   Yalowich J.C.;
RT   "Altered stability of etoposide-induced topoisomerase II-DNA complexes
RT   in resistant human leukaemia K562 cells.";
RL   Br. J. Cancer 69:687-697(1994).
//